Brief Report: Macrophage Activation in HIV-2–Infected Patients Is Less Affected by Antiretroviral Treatment—sCD163 in HIV-1, HIV-2, and HIV-1/2 Dually Infected Patients

    loading  Checking for direct PDF access through Ovid

Abstract

The course of disease among HIV-2, HIV-1, and HIV-1/2 dually infected patients is different. We investigated the macrophage activation marker soluble CD163 (sCD163) dynamics in 212 HIV-1, HIV-2, and HIV-1/2 dually infected patients. There were no differences in sCD163 levels at baseline or during follow-up without antiretroviral therapy (ART). At follow-up on ART, median sCD163 levels were decreased for HIV-1–infected patients (P < 0.001), but not among HIV-2 (P = 0.093) or HIV-1/2 dually infected patients (P = 0.145). The larger decrease in sCD163 levels among HIV-1–infected patients during ART may indicate an HIV type–dependent differential effect of ART on macrophage activation during HIV infection.

Related Topics

    loading  Loading Related Articles